Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia
BD Santomasso, JH Park, D Salloum, I Riviere, J Flynn… - Cancer discovery, 2018 - AACR
CD19-specific chimeric antigen receptor (CAR) T-cell therapy is highly effective against
relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity …
relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity …
Pharmacologic control of CAR-T cell function using dasatinib
Chimeric antigen receptor (CAR) T-cell therapy mediates high response rates in
relapsed/refractory B-cell malignancies. 1, 2, 3, 4 However, some patients experience …
relapsed/refractory B-cell malignancies. 1, 2, 3, 4 However, some patients experience …
CAR T-cell therapy in autoimmune diseases
G Schett, A Mackensen, D Mougiakakos - The Lancet, 2023 - thelancet.com
Despite the tremendous progress in the clinical management of autoimmune diseases,
many patients do not respond to the currently used treatments. Autoreactive B cells play a …
many patients do not respond to the currently used treatments. Autoreactive B cells play a …
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
In the clinic, chimeric antigen receptor–modified T (CAR T) cell therapy is frequently
associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity …
associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity …
Cell therapy for chronic TBI: interim analysis of the randomized controlled STEMTRA trial
M Kawabori, AH Weintraub, H Imai, I Zinkevych… - Neurology, 2021 - AAN Enterprises
Objective To determine whether chronic motor deficits secondary to traumatic brain injury
(TBI) can be improved by implantation of allogeneic modified bone marrow–derived …
(TBI) can be improved by implantation of allogeneic modified bone marrow–derived …
[HTML][HTML] Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
J Zhang, Y Hu, J Yang, W Li, M Zhang, Q Wang… - Nature, 2022 - nature.com
Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL
F Del Bufalo, M Becilli, C Rosignoli… - Blood, The Journal …, 2023 - ashpublications.org
Autologous CD19-directed chimeric antigen receptor (CAR)-T cells have shown
unprecedented efficacy in children with relapsed/refractory B-cell precursor acute …
unprecedented efficacy in children with relapsed/refractory B-cell precursor acute …
BTK blockers make headway in multiple sclerosis
E Dolgin - Nature Biotechnology, 2021 - go.gale.com
BTK blockers make headway in multiple sclerosis - Document - Gale Academic OneFile Use
this link to get back to this page. Copy Skip to Content Library Menu: Google Scholar Discovery …
this link to get back to this page. Copy Skip to Content Library Menu: Google Scholar Discovery …
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
S Ghorashian, AM Kramer, S Onuoha, G Wright… - Nature medicine, 2019 - nature.com
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled
responses in relapsed/refractory acute lymphoblastic leukemia (ALL),,,–, but toxicity …
responses in relapsed/refractory acute lymphoblastic leukemia (ALL),,,–, but toxicity …
[HTML][HTML] CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
BACKGROUND. T cells that have been modified to express a CD19-specific chimeric
antigen receptor (CAR) have antitumor activity in B cell malignancies; however, identification …
antigen receptor (CAR) have antitumor activity in B cell malignancies; however, identification …